 |
 |
|
NEW! PharmaVentures has launched its brand new business television show."PharmaVentures Business Review" is a new cutting-edge television business show that provides you with effortless access to essential industry intelligence. As the first of its kind, we expect this show to be watched by thousands throughout the industry and financial sector. Bringing together a wealth of insightful analysis and debate, PharmaVentures is uniquely placed to present a business review. With over 12 years of experience in supporting successful deals and alliances, our expertise is unbeatable. This monthly broadcast is available in various media formats, including podcast, for you to download and watch at your convenience. |
||
 |
 |
 |
Market News and TrendsDuring April 2006, PharmaDeals Agreements recorded a relatively low number of deals relating to drug delivery, with a total of only 14. The majority of these deals were either between start-up and established companies (5 in total) or between two start-up companies (also 5 in total). Half of the deals were licensing agreements; the remaining 7 comprised collaborative, co-development, evaluation, co-promotion and marketing deals as well as one technology acquisition and one business acquisition. It is interesting to note that 4 of the 14 drug delivery deals recorded in April 2006 focused upon respiratory products while a further two involved the development of sprays for neurological conditions. Read more... |
||
|
|
||
Featured ArticleCationic Emulsion Technology for Lipophilic Drug DeliveryA significant part of the newly developed NCE is lipophilic. As such, their delivery in acceptable pharmaceutical forms presents a challenge for all administration routes. Usually, the first tactic of the formulation expert is the preparation of a solution by adding co-solvents or by pH adjustment in case of ionisable molecules. However, these approaches are not always successful. In this article, Laura Rabinovich-Guilatt and Gregory Lambert of Novagali Pharma, discuss one of the most valuable options offered to poorly soluble compounds: their formulation in emulsions, which are heterogeneous systems in which one immiscible liquid is dispersed as droplets in another. Read more... |
 |
||
|
|
||
 |
Company ProfilesADD Technologies, ALZA, Eurand, Haselmeier |
||
|
|
||
Drug Delivery OpportunitiesView all our Drug Delivery Opportunities or alternatively request a password to submit your opportunity online.Featured Opportunity Compositions and Methods for Targetting Peptides to the CNS Administrative Route - Undisclosed Indication - Alzheimer's disease, Parkinson's disease, prion diseases Licence code - LO-0406-42 |
 |
||
|
|
||
 |
Ensure you receive your copy of the Drug Delivery Report Spring / Summer 2006For deal makers actively assessing drug delivery technology receiving your complimentary copy is a must. The DDR blends high-quality articles covering the latest drug developments in conjunction with concise profiles of companies active in specific technology areas.Apply to receive the next edition of the DDR Find out more about promoting your company |
||
Comprising two specialist areas - PharmaVentures Consulting and PharmaVentures Intelligence - we work with clients to drive greater value from their deals.
If you do not wish to receive DDR E-News in future, please e-mail ddr@pharmamail.biz with the words UNSUBSCRIBE as the subject.
If you do not wish to receive other e-mail communications from PharmaVentures or selected third parties, please e-mail ddr@pharmamail.biz with REMOVE as the subject.
For more details contact
Kate Atherton, Publishing Editor, PharmaVentures Ltd, Magdalen Centre, Oxford Science Park, Oxford OX4 4GA, UK. Tel: +44 (0) 1865 784 177 Fax: +44 (0) 1865 784 178 E-mail ddr@pharmamail.biz